Compare GMM & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | DTIL |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 97.7M |
| IPO Year | 2022 | 2019 |
| Metric | GMM | DTIL |
|---|---|---|
| Price | $1.21 | $4.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 165.7K | 152.6K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 106.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $3.53 |
| 52 Week High | $4.75 | $8.82 |
| Indicator | GMM | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 60.16 |
| Support Level | $1.04 | $4.17 |
| Resistance Level | $3.18 | $4.61 |
| Average True Range (ATR) | 0.15 | 0.26 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 20.99 | 79.89 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.